Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
InnoCare Pharma Limited clinical trials
The registry lists 63 studies whose lead sponsor is InnoCare Pharma Limited or one of 2 companies grouped under it. 36 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 14, 2026.
Keep track of what changes. Save the InnoCare Pharma Limited studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to InnoCare Pharma Limited.
- Beijing InnoCare Pharma Tech Co., Ltd.57 studies →Subsidiary
Something wrong?
- InnoCare Pharma Inc.5 studiesSame company
Something wrong?
- Innocare Pharma Australia Pty Ltd1 study →Regional office
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 50 of 63. Browse all 63 →
- Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo NodularisRecruitingNCT07236099Phase 2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).Not yet recruitingNCT07784101Phase 3
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid MalignanciesRecruitingNCT06656494Phase 1
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjögren's SyndromeNot yet recruitingNCT07727486Phase 2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)RecruitingNCT07082686Phase 2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Evaluation of ICP-B208 in Patients With Advanced Solid TumorsRecruitingNCT07617493Phase 1/2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy SubjectsRecruitingNCT07535099Phase 1
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind StudyRecruitingNCT07440537Phase 2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous UrticariaRecruitingNCT07378527Phase 2/3
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque PsoriasisRecruitingNCT06842199Phase 3
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque PsoriasisRecruitingNCT07251998Phase 2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)RecruitingNCT06378138Phase 2/3
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone LymphomaRecruitingNCT06082102Phase 3
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System TumorsRecruitingNCT05745623Phase 1/2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- ICP-332 in Subjects With Moderate to Severe Atopic DermatitisRecruitingNCT06775860Phase 3
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- The Study of ICP-248 in Patients With Mature B-cell MalignanciesRecruitingNCT05728658Phase 1
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid TumorsRecruitingNCT04685226Phase 1/2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Evaluation of ICP-B794 in Patients With Advanced Solid TumorsNot yet recruitingNCT07136558Phase 1
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- ICP-332 in Subjects With Non-segmental VitiligoRecruitingNCT07047612Phase 2/3
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell MalignanciesRecruitingNCT06351527Phase 1
Sponsor listed in the registry: InnoCare Pharma Inc.
- Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin LymphomaNot yet recruitingNCT06845241Phase 1/2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCLRecruitingNCT06363994Phase 3
Sponsor listed in the registry: InnoCare Pharma Inc.
- Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic MalignanciesRecruitingNCT05690581Phase 1
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus ErythematosusRecruitingNCT05688696Phase 2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06521255Phase 3
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune ThrombocytopeniaRecruitingNCT06004856Phase 3
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT05719701Phase 1/2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial CancerRecruitingNCT04492293Phase 2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell LymphomaRecruitingNCT05234684Phase 3
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic CholangiocarcinomaRecruitingNCT05678270Phase 2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- A Study of ICP-033 in Patients With Advanced Solid TumorsRecruitingNCT05367232Phase 1
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy SubjectRecruitingNCT05684653Phase 1
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLLRecruitingNCT04578613Phase 3
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic DermatitisRecruitingNCT05702268Phase 2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCLRecruitingNCT05552937Phase 2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid TumorsNot yet recruitingNCT05370755Phase 1
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Evaluating Different Doses of Orelabrutinib in MCLCompletedNCT05978739Phase 2
Sponsor listed in the registry: InnoCare Pharma Inc.
- A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)CompletedNCT03494179Phase 1/2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell MalignanciesActive, not recruitingNCT04014205Phase 1/2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Phase I Study of ICP-332 in Healthy SubjectsCompletedNCT06530966Phase 1
Sponsor listed in the registry: InnoCare Pharma Inc.
- A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell LymphomaCompletedNCT05051891Phase 3
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque PsoriasisCompletedNCT06109818Phase 2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- A Study of ICP-022 in Patients With R/R DLBCLCompletedNCT04438005Phase 2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom MacroglobulinemiaCompletedNCT04440059Phase 2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)CompletedNCT03797456Phase 2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell LymphomaActive, not recruitingNCT04304040Phase 1/2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple SclerosisActive, not recruitingNCT04711148Phase 2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- A Clinical Study of ICP-488 in Healthy Subjects and Patients With PsoriasisStatus unknownNCT05451199Phase 1
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- A Study of ICP-192 in Patients With Advanced Solid TumorsStatus unknownNCT04565275Phase 1/2
Sponsor listed in the registry: Beijing InnoCare Pharma Tech Co., Ltd.
- Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid TumorsStatus unknownNCT05537987Phase 1
Sponsor listed in the registry: InnoCare Pharma Inc.